⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 1, 2025

Licochalcone A ameliorates lipid accumulation in metabolic dysfunction-associated steatotic liver disease via upregulating PPARα/CPT1α.

Wenrui Zhu Hongfeng Xu Rui Yan L. Qiu Guojun Wang Yantao Zhu

View Full Paper

Ask AI

Bookmark

Share

Key Points

Licochalcone A reduces lipid accumulation, indicating a positive impact on liver health.
The treatment improved lipid metabolism disorder in MASLD mice by targeting specific pathways.
Assessment utilized signaling pathway analysis to evaluate the effects on metabolic function.
This research highlights the potential for therapeutic strategies against metabolic liver diseases.

Implication

Findings demonstrate Licochalcone A enhanced lipid metabolism in MASLD mice, suggesting potential liver disease benefits.

Abstract

This study demonstrated that LiA ameliorates the lipid metabolism disorder in MASLD mice by upregulating the PPARα/CPT1α signaling pathway.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/694027632d562116f28ffead https://doi.org/10.14670/hh-18-907

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Dietpreclinical · 2019 · 158 citations
2Multi-omics strategies combined with molecular docking to explore the regulatory effects of licochalcone A on glycolipid metabolism in db/db micepreclinical · 2025 · 1 citations
3Licochalcone E Ameliorates Hepatic Steatosis in Obese Mice by Activating the Sirt1/AMPK Pathway and Reducing Hepatic Lipid Accumulation.Original Research · 2026
4Hepatic-Metabolic Activity of α-Lipoic Acid—Its Influence on Sphingolipid Metabolism and PI3K/Akt/mTOR Pathway in a Rat Model of Metabolic Dysfunction-Associated Steatotic Liver Disease2024 · 10 citations
5Overexpression of Apolipoprotein A-I Alleviates Insulin Resistance in MASLD Mice Through the PPARα Pathwaypreclinical · 2025 · 4 citations